Ocugen Announces That The Data And Safety Monitoring Board For The OCU200 Clinical Trial Recently Convened And Reviewed Safety Data Following Dosing Of The First Cohort In The Dose-Escalation Portion Of The Phase 1 Study And Approved Continuation Of Dosin